Discontinued operations and assets held for sale (Tables)
|
12 Months Ended |
Dec. 31, 2025 |
|---|
| Disclosure of analysis of single amount of off-balance sheet arrangements [line items] |
|
| Schedule of consideration received |
| | | | | | Year ended December 31, 2024 | | | (Euro,
in thousands) | Upfront payment received | | € | 50,000 | Settlement for net cash and working capital | | | 9,835 | Total consideration received | | € | 59,835 |
|
| Schedule of assets and liabilities over which control was lost |
| | | | | | January 31, 2024 | | | (Euro,
in thousands) | Property, plant and equipment | | € | 4,186 | Deferred tax assets | | | 292 | Other non-current assets | | | 613 | Inventories | | | 505 | Trade and other receivables | | | 18,439 | Cash and cash equivalents | | | 19,523 | Other current assets | | | 1,161 | Total assets | | | 44,719 | | | | | Other reserves | | | (74) | Retirement benefit liabilities | | | 1,003 | Non-current lease liabilities | | | 2,328 | Other non-current liabilities | | | 90 | Current lease liabilities | | | 1,308 | Trade and other liabilities | | | 28,927 | Current tax payable | | | 1,170 | Current deferred income | | | 430 | Total liabilities | | | 35,182 | | | | | Net assets disposed of | | € | 9,537 |
|
| Schedule of gain or loss on disposal of subsidiaries. |
| | | | | | Year ended December 31, 2024 | | | (Euro,
in thousands) | Upfront payment received | | € | 50,000 | Settlement for net cash and working capital | | | 9,835 | Additional adjustment working capital to be settled | | | (750) | Net assets disposed of | | | (9,537) | Effect of cumulative translation adjustments reclassified from equity on loss of control | | | (4,095) | Fair value of the future earn-outs payable by Alfasigma to us | | | 47,035 | Contribution for R&D costs payable by us to Alfasigma | | | (40,000) | Gain on disposal of subsidiaries | | € | 52,488 |
|
| Schedule of net cash flow on disposal of subsidiaries |
| | | | | | | | | Year ended December 31, | | | | 2025 | | | 2024 | | | | (Euro,
in thousands) | Upfront payment received | | € | — | | € | 50,000 | Settlement for net cash and working capital | | | — | | | 9,835 | Release from/transfer to (-) escrow account | | | 24,806 | | | (40,000) | Contribution for R&D costs paid by us to Alfasigma | | | (25,000) | | | (15,000) | Earn-outs paid by Alfasigma | | | 7,432 | | | 2,053 | Less: cash and cash equivalents balances disposed of | | | — | | | (19,523) | Less: settlement of pre-existing relationships | | | — | | | 3,686 | Cash in/out (-) from disposals of subsidiaries, net of cash disposed of | | € | 7,238 | | € | (8,949) | | | | | | | | | | | | | | | Costs associated to the sale taken into result in 2023 | | € | — | | € | (3,072) | Costs associated to the sale taken into result in 2024 | | | — | | | (526) | Cash used for other liabilities related to the disposal of subsidiaries | | € | — | | € | (3,598) |
|
| Schedule of financial statements in relation to the discontinued operations |
| | | | | | | | | | | | Year ended December 31, | | | 2025 | | 2024 | | 2023 | | | | (Euro, in thousands, except share and per share data) | | | | | | | | | | | Product net sales | | € | — | | € | 11,475 | | € | 112,339 | Collaboration revenues | | | — | | | 26,041 | | | 431,465 | Total net revenues | | | — | | | 37,516 | | | 543,804 | | | | | | | | | | | Cost of sales | | | — | | | (1,693) | | | (18,022) | Research and development expenses | | | (11,708) | | | (8,152) | | | (190,177) | Sales and marketing expenses | | | (932) | | | (11,520) | | | (113,356) | General and administrative expenses | | | (94) | | | (1,087) | | | (17,989) | Other operating income | | | 11,933 | | | 56,180 | | | 13,003 | | | | | | | | | | | Operating profit/loss (-) | | | (801) | | | 71,244 | | | 217,262 | | | | | | | | | | | Fair value adjustments and net currency exchange differences | | | — | | | — | | | (13) | Other financial income | | | 2,676 | | | 4,230 | | | 679 | Other financial expenses | | | — | | | (12) | | | (167) | | | | | | | | | | | Profit before tax | | | 1,875 | | | 75,462 | | | 217,761 | | | | | | | | | | | Income taxes | | | (483) | | | (98) | | | (2,076) | | | | | | | | | | | Net profit | | € | 1,392 | | € | 75,364 | | € | 215,685 | | | | | | | | | | | Basic and diluted earnings per share from discontinued operations | | € | 0.02 | | € | 1.14 | | € | 3.27 | Weighted average number of shares - Basic (in thousands of shares) | | | 65,897 | | | 65,897 | | | 65,884 | Weighted average number of shares - Diluted (in thousands of shares) | | | 65,901 | | | 65,942 | | | 65,933 |
|
| Schedule of cash flow from discontinued operations related to Jyseleca business. |
| | | | | | | | | | | | 2025 | | 2024 | | 2023 | | | | | (Euro,
in thousands) | Net cash flow used in operating activities | | € | (851) | | € | (36,367) | | € | (175,627) | Net cash flow generated from/used in (-) investing activities | | | 7,238 | | | (8,949) | | | (105) | Net cash flow used in financing activities | | | — | | | — | | | (1,928) | Net cash flow generated from/used in (-) discontinued operations | | € | 6,387 | | € | (45,316) | | € | (177,660) |
|
| Galapagos Real Estate Belgium NV [member] |
|
| Disclosure of analysis of single amount of off-balance sheet arrangements [line items] |
|
| Schedule of consideration received |
| | | | | | Year ended December 31, 2025 | | | (Euro,
in thousands) | Payment received | | € | 12,206 | Total consideration received | | € | 12,206 |
|
| Schedule of assets and liabilities over which control was lost |
| | | | | | March 31, 2025 | | | (Euro,
in thousands) | Property, plant and equipment | | € | 11,115 | Trade and other receivables | | | 1 | Cash and cash equivalents | | | 13 | Total assets | | | 11,129 | | | | | Trade and other liabilities | | | 11,020 | Total liabilities | | | 11,020 | | | | | Net assets disposed of | | € | 109 |
|
| Schedule of gain or loss on disposal of subsidiaries. |
| | | | | | Year ended December 31, 2025 | | | (Euro,
in thousands) | Payment received | | € | 12,206 | Settlement of intercompany loan | | | (11,012) | Net assets disposed of | | | (109) | Gain on disposal of subsidiaries | | € | 1,085 |
|
| Schedule of net cash flow on disposal of subsidiaries |
| | | | | | Year ended December 31, 2025 | | | (Euro,
in thousands) | Payment received | | € | 12,206 | Less: cash and cash equivalents balances disposed of | | | (13) | Cash in from disposal of subsidiaries, net of cash disposed of | | € | 12,193 |
|